Novo Nordisk led the weight loss drug boom. Now it’s catch-up time
In the late 2010s, scientists at the Danish drugmaker Novo Nordisk developed a new weekly obesity treatment that targeted three hormones at once. In mice studies, the drug, which activated receptors of the GLP-1, GIP, and glucagon hormones, caused notable weight loss. But Novo shelved the therapy. The company was concerned about potential side effects … [Read more…]